Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,051,918
  • Shares Outstanding, K 114,588
  • Annual Sales, $ 46,550 K
  • Annual Income, $ -75,240 K
  • 60-Month Beta 1.23
  • Price/Sales 22.87
  • Price/Cash Flow N/A
  • Price/Book 10.67
Trade DVAX with:

Options Overview

Details
  • Implied Volatility 75.29%
  • Historical Volatility 32.59%
  • IV Percentile 3%
  • IV Rank 6.33%
  • IV High 213.51% on 02/01/21
  • IV Low 65.95% on 05/28/21
  • Put/Call Vol Ratio 0.21
  • Today's Volume 797
  • Volume Avg (30-Day) 1,609
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 57,574
  • Open Int (30-Day) 57,234

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.05
  • Number of Estimates 3
  • High Estimate 0.05
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +81.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.39 +22.06%
on 05/19/21
9.56 -5.65%
on 06/10/21
+1.22 (+15.64%)
since 05/14/21
3-Month
7.09 +27.22%
on 05/11/21
11.84 -23.82%
on 04/19/21
-0.56 (-5.85%)
since 03/12/21
52-Week
3.58 +151.96%
on 10/29/20
12.44 -27.49%
on 07/20/20
+3.31 (+57.97%)
since 06/12/20

Most Recent Stories

More News
Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

/PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will present virtually at the Goldman...

DVAX : 9.02 (-1.74%)
Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030

Reportlinker.com announces the release of the report "Oligonucleotide Therapy Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090627/?utm_source=GNW

DVAX : 9.02 (-1.74%)
IONS : 37.79 (-0.37%)
JAZZ : 186.42 (+0.13%)
MRK : 75.45 (-1.08%)
MGEN : 23.01 (-0.09%)
SRPT : 86.12 (+0.14%)
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany

EMERYVILLE, Calif., /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement...

DVAX : 9.02 (-1.74%)
Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B(R) Hepatitis B Vaccine in Germany

COPENHAGEN, Denmark, May 27 2021 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has entered a partnership with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing...

BVNKF : 46.0000 (unch)
DVAX : 9.02 (-1.74%)
Dynavax to Present at the William Blair 41st Annual Growth Stock Conference

, /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will participate in a virtual...

DVAX : 9.02 (-1.74%)
Dynavax Announces Pricing of $200 Million Convertible Senior Notes Offering

EMERYVILLE, Calif., /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced the pricing of $200.0 million aggregate principal amount of 2.50% convertible senior...

DVAX : 9.02 (-1.74%)
Dynavax Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

EMERYVILLE, Calif., /PRNewswire/ -- Dynavax Technologies Corporation ("Dynavax") (Nasdaq: DVAX) today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate...

DVAX : 9.02 (-1.74%)
Dynavax Technologies (DVAX) Beats Q1 Earnings and Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 37.94%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DVAX : 9.02 (-1.74%)
Dynavax Technologies: Q1 Earnings Snapshot

EMERYVILLE, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Thursday reported first-quarter net income of $891,000, after reporting a loss in the same period a year earlier.

DVAX : 9.02 (-1.74%)
Dynavax Announces First Quarter 2021 Financial Results

, /PRNewswire/ --  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the first quarter of 2021.

DVAX : 9.02 (-1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development...

See More

Key Turning Points

3rd Resistance Point 9.59
2nd Resistance Point 9.45
1st Resistance Point 9.24
Last Price 9.02
1st Support Level 8.89
2nd Support Level 8.75
3rd Support Level 8.54

See More

52-Week High 12.44
Fibonacci 61.8% 9.06
Last Price 9.02
Fibonacci 50% 8.01
Fibonacci 38.2% 6.96
52-Week Low 3.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar